VitriVax Secures $17.25M in Series B Funding for Advanced Vaccine Technology

VitriVax, Inc. raises $17.25M for proprietary ALTA technology with support from Adjuvant Capital and RA Capital Management, LP

AI-assisted, human-published

Latest headlines

Join us for funding and investment opportunities.

Stay connected!

If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here